BioNTech has abruptly terminated a Phase 2 trial of its experimental personalized mRNA cancer “vaccine” after an independent safety board identified an alarming imbalance in overall survival between the treatment groups.
The trial, known as BNT122-01 (NCT04486378), enrolled approximately 327 patients with surgically resected high-risk Stage II or Stage III colorectal cancer who remained positive for circulating tumor DNA. Participants were randomized to receive BioNTech’s individualized mRNA cancer immunotherapy, autogene cevumeran (BNT122/RO7198457), or watchful waiting.
Patients in the mRNA arm underwent an aggressive hyper-dosing regimen of up to 15 intravenous infusions over roughly one year—six weekly doses across the first six treatment weeks, two more at two-week intervals over the following month, followed by seven additional doses every six weeks for the remainder of the year.
The independent Data Safety Monitoring Board has now reported a “numerical imbalance in overall survival between treatment arms” and concluded that continuing the study was unlikely to change its efficacy outcome. It recommended that treatment be stopped and the entire clinical trial terminated. BioNTech surprisingly accepted the recommendation.
In lay terms, overall survival measures how long patients remain alive after entering the trial. An imbalance therefore represents a mortality signal between the groups. BioNTech has not yet disclosed the number of deaths in each arm, the mortality rates, hazard ratio, causes of death, or which treatment group experienced poorer survival.
Perhaps even more concerning, the trial had already crossed a prespecified futility boundary in October 2025, indicating that the accumulating results were unlikely to demonstrate the intended efficacy. BioNTech nevertheless continued the study.
As the vaccine cartel races to push mRNA technology into an ever-expanding list of diseases, this trial marks yet another major failure of the platform—this time in cancer patients, where the stakes could not be higher. It’s time to END the unchecked expansion of mRNA technology and protect innocent civilians from further death and disability.
Epidemiologist and Foundation Administrator, McCullough Foundation
Support our mission: mcculloughfnd.org
Please consider following both the McCullough Foundation and my personal account on X (formerly Twitter) for further content.
IPAK-EDU is grateful to FOCAL POINTS (Courageous Discourse™) as this piece was originally published there and is included in this news feed with mutual agreement. Read More
Leave a Reply